Steven Dowdy’s Marathon Study Revealed
Steven Dowdy has dedicated himself to finding ways to deliver RNA drugs into cells. These molecules target genetic causes of diseases; however, their negatively charged molecules tend to repel cell membranes; so Steven devised a solution.
This work was published in Nature Biotechnology. To conduct their experiment, scientists employed an RNA form that can transport sugars directly into cell membranes.
Early Life and Education
Eight years can be a long time for scientists to keep their work under wraps, but that suspense finally ended for University of California San Diego researcher Steven Dowdy when his marathon study was published by Nature Biotechnology on Nov 17th.
Work involves administering a new class of drugs known as RNA Interference (RNAi) drugs to cells to stop diseases at their genetic source with extreme precision.
His RNAi research employs molecules that protect a drug from being rejected by cell membranes; once inside, enzymes break off its protective coating and activate it, activating its prodrug form.
This work employs a novel delivery mechanism in which an RNAi trigger is attached to sugar molecules for delivery, providing researchers with a tool to develop more RNAi medicines for various diseases.
Steven Dowdy is an Associate Professor in Cellular and Molecular Medicine at University of California San Diego School of Medicine, as well as the Damon Runyon postdoctoral fellow of Whitehead Institute MIT. His primary areas of research are G1 cell cycle control and RNAi therapeutics; additionally he serves on Scientific Advisory Boards such as Deep Genomics and NeuBase Therapeutics.
He has published more than 100 peer-reviewed papers and earned a PhD in molecular genetics from UC Irvine with Eric Stanbridge studying tumor suppressor genes before working as a postdoc with Bob Weinberg at the Whitehead Institute of Biomedical Research, MIT.
He is an internal medicine specialist in Marquette, Michigan affiliated with UP Health System-Marquette and received his medical degree from Lake Erie College of Osteopathic Medicine – Seton Hill. He has been practicing between 11-20 years.
Achievement and Honors
Dowdy Laboratory specializes in developing and administering RNAi therapeutics and G1 cell cycle control treatments in cancer. Additionally, its expertise lies in synthesizing prodrug triggers with neutral bioreversible phosphotriester backbones which enhance metabolic stability while simultaneously improving pharmacokinetics.
Professor of Cellular and Molecular Medicine at the University of California San Diego School of Medicine. Additionally, he serves on both Deep Genomics’ and NeuBase Therapeutics Scientific Advisory Boards as well as being an investigator of Howard Hughes Medical Institute.
Dowdy-Ficklen Stadium and Dowdy Student Stores bear his name, while he was also one of ECU’s founding Chancellor’s Society members, Order of the Cupola members, and served on its Board of Trustees.
Steven Dowdy lives in California with his wife and two children, where he serves as professor of cellular and molecular medicine at the University of California San Diego School of Medicine. His research interests center on novel therapeutic delivery – particularly RNAi therapies – into cells. Steven is a Damon Runyon Cancer Research Foundation Fellow as well as former investigator with Howard Hughes Medical Institute.
John serves on the Scientific Advisory Boards for both Deep Genomics and NeuBase Therapeutics, and is a member of Oligonucleotide Therapeutics Society. Additionally, he has published over 100 peer-reviewed papers.
Steven Dowdy of UC San Diego faced a career-altering test after leading an eight-year study published in Nature Biotechnology that demonstrated an innovative method for delivering RNA drugs into cells, combatting genetic disease.
Landon Dowdy, an American journalist and reporter, has become increasingly well-known since joining CNBC in 2014 to host shows such as ‘Worldwide Exchange’ and ‘On the Money’. She has also contributed her expertise to NBC and Golf Channel; though she remains fairly private.
Robert Dowdy currently boasts an estimated net worth of approximately $444 Thousand. This wealth has been amassed through both his work and investments in Weyerhaeuser Co stock; over the course of 19 years, he sold more than 15,000 shares.